Changes in DNA After Radiation Therapy in Patients With Prostate Cancer
- Conditions
- Prostate Cancer
- Registration Number
- NCT00899912
- Lead Sponsor
- Radiation Therapy Oncology Group
- Brief Summary
RATIONALE: Collecting and storing samples of tissue from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA after radiation therapy and identify biomarkers related to cancer.
PURPOSE: This laboratory study is looking at changes in DNA after radiation therapy in patients with prostate cancer.
- Detailed Description
OBJECTIVES:
Primary
* Demonstrate the feasibility of acquiring specimens, both frozen and paraffin-embedded, to yield RNA of adequate quality to perform DNA microarray studies on markers of radiotherapy outcome in patients with intermediate-risk prostate cancer.
Secondary
* Compare the gene expression results from frozen tissue and paraffin-embedded tissue to see the correlation between the 2 methods in patients treated on the brachytherapy alone arm of protocol RTOG-0232.
* Find genes that are expressed differentially before and after radiation therapy in patients treated on the brachytherapy plus external-beam radiation therapy arm of protocol RTOG-0232.
* Find gene expression patterns in patients treated on either arm of protocol RTOG-0232 who have significant associations with biochemically as well as clinically apparent local and distant failure.
OUTLINE: This is a multicenter, pilot study.
Frozen and paraffin-embedded tissue samples are studied for biomarker/laboratory analysis. DNA microarray analysis is performed on the samples to assess markers of radiotherapy outcome.
PROJECTED ACCRUAL: A total of 156 patients will be accrued for this study.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 13
- Histologically confirmed, locally confined adenocarcinoma of the prostate
- Zubrod performance 0-1
- Clinical stages T1c - T2b, N0, M0
- Combined Gleason score 7 if prostate specific antigen (PSA) < 10, combined Gleason score < 7 if PSA 10 - 20; PSA must be ≤ 20 ng/mL, before hormone therapy, if given, and a prostate volume by transrectal ultrasound (TRUS) ≤ 60 cc.
- American Urological Association (AUA) score ≤ 15 (alpha blockers are allowed).
- Age ≥ 18 years old and must sign a study-specific informed consent form
- No clinically or pathologically involved lymph nodes
- No distant metastases or significant obstructive symptoms
- No prior chemotherapy, pelvic radiation, transurethral prostatectomy (TURP), cryosurgery, TUNA, transurethral microwave thermotherapy (TUMT) or radical surgery for carcinoma of the prostate is allowed.
- No previous hormonal therapy beginning < 2 months or > 6 months prior to registration is allowed.
- No previous or concurrent cancers other than basal, in situ, or squamous cell skin cancers unless the patient is disease free for ≥ 5 years.
- No hip prosthesis or major medical or psychiatric illnesses are allowed. prior to study entry.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Number of frozen and paraffin-embedded specimens that yield adequate RNA for tumor tissue microarray analysis Specimens collected at the time of brachytherapy
- Secondary Outcome Measures
Name Time Method Gene expression patterns in patients treated on either arm of protocol RTOG-0232 who have significant associations with biochemically as well as clinically apparent local and distant failure After microarray analysis of tissue and primary endpoint analysis of RTOG 0232 Comparison of genes to determine which are expressed differentially before and after radiotherapy in patients treated on the brachytherapy plus external-beam radiation therapy arm of protocol RTOG-0232 After microarray analysis of tissue and primary endpoint analysis of RTOG 0232 Comparison of gene expression patterns between frozen and paraffin-embedded tissue in patients treated on the brachytherapy alone arm of protocol RTOG-0232 After microarray analysis of tissue and primary endpoint analysis of RTOG 0232
Trial Locations
- Locations (10)
Fox Chase Cancer Center - Philadelphia
🇺🇸Philadelphia, Pennsylvania, United States
Georgia Cancer Center for Excellence at Grady Memorial Hospital
🇺🇸Atlanta, Georgia, United States
Emory Crawford Long Hospital
🇺🇸Atlanta, Georgia, United States
Winship Cancer Institute of Emory University
🇺🇸Atlanta, Georgia, United States
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
🇺🇸Saint Louis, Missouri, United States
MedCentral - Mansfield Hospital
🇺🇸Mansfield, Ohio, United States
Barnes-Jewish West County Hospital
🇺🇸Saint Louis, Missouri, United States
Cancer Institute at St. John's Hospital
🇺🇸Springfield, Illinois, United States
Siteman Cancer Center at Barnes-Jewish St. Peters Hospital - St. Peters
🇺🇸Saint Peters, Missouri, United States
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
🇺🇸Columbus, Ohio, United States